论文部分内容阅读
杂交瘤技术产生的单克隆抗体为区别人体恶性黑色素瘤和其他肿瘤抗原增加了一种新的方法。这种独特的IgG_3抗体R-24具有血清学的特异性和免疫学的特点,从而已促进临床试用R-24治疗黑色素瘤患者。单克隆抗体对人黑色素瘤异种移植的作用近来,研究人员已表明单克隆IgG_3抗体能识别GD_3神经节苷脂抗原。人恶性黑色素瘤在裸鼠体内的小的移植物,在反复静脉给予GD_3特异性抗体2B_2后消失, GD_2是起源于神经外胚层肿瘤的另一种神经节苷脂的抗原。当用这种IgM抗体和培养的
Monoclonal antibodies produced by hybridoma technology add a new method for distinguishing human malignant melanoma from other tumor antigens. This unique IgG3 antibody, R-24, is serologically specific and immunogenic and has led to clinical trials of R-24 in patients with melanoma. Effect of monoclonal antibodies on human melanoma xenografts Recently, researchers have shown that monoclonal IgG3 antibodies recognize GD3 ganglioside antigens. Small transplants of human malignant melanoma in nude mice disappeared after repeated intravenous administration of the GD 3 specific antibody 2B 2, which is an antigen of another ganglioside derived from tumors of neuroectodermal tumors. When using this IgM antibody and cultured